←
Maria Moscvin504 posts
Maria Moscvin avatar

Maria Moscvin

@MMoscvin

@UChicagoHemOnc Fellow | alum @StanfordMedRes @TheBianchiLab @DanaFarber @unito 🇮🇹

◷ Joined July 2020▧ 76 Photos and videos
Maria Moscvin avatar
Maria Moscvin@MMoscvin·3h

Another contradictory result, Li et al in @AnnSurgOncol show that pre-operative myasthenia is associated with worse outcomes at 5-years in thymoma patients, 8.6-point difference in OS and 7.6 points for recurrence favoring patients who did not have MG. link.springer.com/article/10…

Stephen V Liu, MD avatar
⟳ Maria Moscvin retweeted
Stephen V Liu, MD@StephenVLiu·23h

FDA grants accelerated approval to neladalkib (NVL-655) for advanced ALK positive NSCLC with prior TKI therapy. Based on ALKOVE-1 study - post alectinib RR 49%, more than half of responses ongoing at a year. Favorable tox profile. New best in class? fda.gov/drugs/cancer-approva…

Alfredo Addeo MD avatar
⟳ Maria Moscvin retweeted
Alfredo Addeo MD@Alfdoc2·Nov 17

Can MTAP deletion become an actionable Achilles’ heel in cancer? Pleased to share our review in The Oncologist on the MTAP–PRMT5 synthetic lethal axis: MTA-cooperative inhibitors, early clinical signals, biomarkers and resistance. @gbanna74 @OncJournal 🔗 doi.org/10.1093/oncolo/oyag4… kudos to the co-authors for their effort @Maxime_Borgeaud @mihaela_aldea dr Koessler and Dr Genoud @hug_ge @DOncologie

Hidehito HORINOUCHI avatar
⟳ Maria Moscvin retweeted
Hidehito HORINOUCHI@HHorinouchi·Nov 15

🔥AI-based prediction of actionable genomic alterations from H&E-stained slides — Perspective 🆙 @Nature_NPJ Precision Oncology 🎯Deep learning predicts AGAs (e.g., EGFR in NSCLC, FGFR in urothelial) directly from routine H&E; EAGLE & ANNAR trials 🎯Near-instant, non-destructive triage for molecular testing & trials at diagnosis; pragmatic integration pathway outlined 🎙Dr. Woochan Hwang @VivekSubbiah #LCSM @OncoAlert @Larvol @EGFRResisters nature.com/articles/s41698-0…

Maria Moscvin avatar
Maria Moscvin@MMoscvin·Nov 15

Are we seeing the ramp-up for thymic tumors similar to what happened for lung cancer? We owe our patients more innovative tools, therapeutic avenues, and closer collaborations, and #ITMIG26 is all about that.

Post attachmentPost attachmentPost attachmentPost attachment
Jordi Remon avatar
⟳ Maria Moscvin retweeted
Jordi Remon@JordiRemon·Nov 14

📓 Final PECATI trial supports PEMBRO + LENVATINIB in pretreated met B3 thymoma & thymic Ca. 📊 mINV-PFS: 22 mo | OS: 40 mo 🚀 Can IO, ADCs & bispecifics move to 1st line? 💪🏻 More academic & pharma collaboration is needed in rare thoracic malignancies! 🔗 authors.elsevier.com/a/1o6FL…

Post attachment
Maria Moscvin avatar
Maria Moscvin@MMoscvin·Nov 12

In thymoma, autoimmunity affects 40% of pts and may share one mechanism @NEJM: AIRE loss → increase IFNγ–JAK–STAT pathway mimicking APS-1, with decrease in IFNγ and CXCL9 upon Ruxolitinib. Antitumor activity was not evaluated, so caution is needed. nejm.org/doi/10.1056/NEJMc26…

ASH avatar
⟳ Maria Moscvin retweeted
ASH@ASH_hematology·Oct 26

ASH welcomes its newly elected Executive Committee members! 👏 Bringing extensive experience and a shared commitment to advancing hematology, these leaders will help guide the Society's work in the years ahead. Read the full announcement: ow.ly/1TWf5100YrV

Post attachmentPost attachment